Used in research for targeted protein degradation, particularly in oncology studies. Acts as a PROTAC (proteolysis-targeting chimera) molecule, designed to selectively degrade specific disease-causing proteins by recruiting E3 ubiquitin ligases. Shows potential in disrupting cancer cell signaling pathways by removing key regulatory proteins. Investigated for its efficacy in hematological malignancies and solid tumors due to its ability to target proteins previously considered "undruggable." Currently in preclinical development stages, serving as a tool compound for validating novel therapeutic targets and optimizing degradation efficiency.